GE Healthcare boosts profits; FDA rejects Alimera's eye implant again;

@FierceMedDev:  buying implant outfit for $80M with eye on Europe. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Roche is closing down its 454 Life Sciences gene sequencing division. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: FierceMedicalDevices' 2013 Fierce 15. Special report | Follow @MichaelGFierce

> GE Healthcare ($GE) boosted its third-quarter profits despite flat sales. Story

> For the third time, the FDA has rejected Alimera Sciences ($ALIM) and pSivida's ($PSDV) Iluvien, a back-of-the-eye implant that delivers a drug to treat diabetic vision loss. Story

> U.S.-based National Instruments has signed a memorandum of understanding with The Healthcare Technology Innovation Center in India to develop new, affordable medical devices. Story

> Researchers from Columbia University Medical Center found in a study that a narrow spectrum of UV light was effective in killing bacteria such as MRSA and didn't harm human skin. Item

> A new study concludes that CT and MRI machines are overused for headaches, despite recommendations against the practice. Story

> General Electric is seeking a patent for an electromagnetic system that would be designed to detect medical instruments in use during surgery, spotting where they are within a patient during a procedure. Story

Biotech News

@FierceBiotech: VC funding follows tepid pace in Q3 as first-time rounds shrivel. Special report | Follow @FierceBiotech

@JohnCFierce: Seamus Fernandez is downgrading Sanofi. Likes PCSK9 but thinks prospects are overblown. Lotso competition coming. Very sensible assessment. | Follow @JohnCFierce

@DamianFierce: The third time is not whatsoever charming as Alimera, pSivida get another FDA rejection for Iluvien. Article | Follow @DamianFierce

@EmilyMFierce: Mini pancreas grown in lab using mouse cells. Story from FierceBiotech Research | Follow @EmilyMFierce

> Boehringer snags EU nods for COPD drug as FDA awaits. More

> Bullish Relypsa eyes $138M in bumped-up IPO pitch. Story

> Blood clots force Ariad to shutter PhIII Iclusig trial. Article

Pharma News

@FiercePharma: Biggest story this a.m. online: Pharma dealmakers, listen up; Ireland may close a popular tax loophole. Story | Follow @FiercePharma

@EricPFierce: Another gut check for Amarin and its fish oil drug . F panel votes against wider use. Article | Follow @EricPFierce

@CarlyHFierce: Q3 earnings: Abbott ups dividend, Actelion confirms growth, Baxter hurt by merger costs. More | Follow @CarlyHFierce

> Valeant ordered to pay Anacor $100M. Story

> EP Vantage: Eliquis projected sales off 60% for 2014. Article

> NICE panel likes Astellas' Xtandi. More

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,